Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCD | Q05655 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21664446 | 0.98 | CA2 (0.41) | PRKCDCA2CA1ZDHHC7KMT2A | |
| SCHEMBL18639268 | 0.98 | CA2 (0.41) | PRKCDCA2CA1ZDHHC7KMT2A | |
| SCHEMBL19749275 | 0.98 | CA2 (0.41) | PRKCDCA2CA1ZDHHC7KMT2A | |
| SCHEMBL23256441 | 0.98 | CA2 (0.41) | PRKCDCA2CA1ZDHHC7KMT2A | |
| SCHEMBL19404107 | 0.98 | CA2 (0.41) | PRKCDCA2CA1ZDHHC7KMT2A | |
| SCHEMBL24974748 | 0.98 | CA2 (0.41) | PRKCDCA2CA1ZDHHC7KMT2A | |
| SCHEMBL18849861 | 0.98 | CA2 (0.41) | PRKCDCA2CA1ZDHHC7KMT2A | |
| SCHEMBL20624783 | 0.98 | CA2 (0.41) | PRKCDCA2CA1ZDHHC7KMT2A | |
| SCHEMBL23877035 | 0.97 | PRKCD (0.38) | PRKCDCA2CA1ZDHHC7KMT2A | |
| SCHEMBL20624810 | 0.97 | CA2 (0.44) | PRKCDCA2CA1ZDHHC7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323167-B2 | Method of treatment with modified arginine deiminase | POLARIS GROUP (TW) | 2008-01-29 | — | — | US | disclosed |
| US-7323167-B2 | Method of treatment with modified arginine deiminase | POLARIS GROUP (TW) | 2008-01-29 | — | — | US | disclosed |
| US-20070172469-A1 | Methods For Inhibiting Viral Replication In Vivo | PHOENIX PHARMACOLOGICS, INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070172469-A1 | Methods For Inhibiting Viral Replication In Vivo | PHOENIX PHARMACOLOGICS, INC. | 2007-07-26 | — | — | US | disclosed |
| US-7204980-B2 | Methods for inhibiting viral replication in vivo | PHOENIX PHARMACOLOGICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7204980-B2 | Methods for inhibiting viral replication in vivo | PHOENIX PHARMACOLOGICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172469-A1 | Methods For Inhibiting Viral Replication In Vivo | EIF2AK2, DIMT1, STING1 | PRKCD 2245/4885CA2 3672/4885CA1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.